К Вопросу Влияния Гормонов На Функцию Сердца
Keywords:
сердце, гормоны, щитовидная железа, гипофункция, гиперфункция, надпочечники, гипофиз, патофизиология
Abstract
В этом обзоре исследуется важность нормальной эндокринной функции для здоровья сердечно-сосудистой системы и обсуждается влияние нарушений эндокринной системы, таких как гиперфункция и гипофункция гормонов, на сердечно-сосудистую систему. Он охватывает эпидемиологию, диагностику и лечение заболеваний, поражающих гипофиз, щитовидную железу, паращитовидные железы и надпочечники, а также рассматривает влияние эндокринной дисфункции на здоровье сердечно-сосудистой системы. Кроме того, в обзоре исследуются преимущества сердечно-сосудистой системы, связанные с восстановлением нормальной эндокринной функции.
References
1. Abs R., Feldt-Rasmussen U., Mattsson A.F. et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis European //J. Endocrinol. - 2006. - Vol. 155. - P. 79-90.
2. Beshyah S.A., Henderson A., Niththyananthan R. et al. The effect of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance // J. Clin.Endocrinol. Metab. - 1995. - Vol. 80. - P. 356-363.
3. Casanueva FF, Molitch ME, Schelechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006; 65:265-73.
4. Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinemia. Clin Endocrinol (Oxf). 2010; 73:369-74.
5. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007; 356:39-46.
6. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356: 29-38.
7. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperpro-lactinemia: a meta-analysis from clinical studies. J Endocrinol Invest. 2008; 31:1119-23
8. Valassi E, Klibanski A, Biller BM. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010;95: 1025-33.
9. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardio-myopathy. Cell. 2007; 128:589-600.
10. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12: 767-78.
2. Beshyah S.A., Henderson A., Niththyananthan R. et al. The effect of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance // J. Clin.Endocrinol. Metab. - 1995. - Vol. 80. - P. 356-363.
3. Casanueva FF, Molitch ME, Schelechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006; 65:265-73.
4. Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinemia. Clin Endocrinol (Oxf). 2010; 73:369-74.
5. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007; 356:39-46.
6. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356: 29-38.
7. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperpro-lactinemia: a meta-analysis from clinical studies. J Endocrinol Invest. 2008; 31:1119-23
8. Valassi E, Klibanski A, Biller BM. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010;95: 1025-33.
9. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardio-myopathy. Cell. 2007; 128:589-600.
10. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12: 767-78.
Published
2023-09-27
How to Cite
Петровна, А. В., Алексеевич, Л. Е., & Азизовна, Т. З. (2023). К Вопросу Влияния Гормонов На Функцию Сердца. Central Asian Journal of Medical and Natural Science, 4(5), 280-287. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1817
Section
Articles
